Immunic Therapeutics (Nasdaq: IMUX) is proud to announce the successful raising of $5,100,000 in its most recent funding round鈥攁 significant milestone that reinforces its commitment to transforming the landscape of chronic inflammatory and autoimmune disease treatment. As a pioneering biotechnology company, Immunic develops a robust clinical pipeline of orally administered, small molecule therapies that aim to provide patients with more convenient, effective, and less invasive alternatives compared to traditional treatments. This infusion of capital will be strategically deployed to accelerate research and clinical development efforts, with the primary focus on advancing its promising portfolio of clinical candidates toward new phase trials. The funds will not only support ongoing studies but also enable the expansion of preclinical research initiatives designed to explore innovative therapeutic mechanisms, ultimately positioning Immunic to address unmet medical needs and improve patient outcomes. With a clear vision to innovate and a dedication to science-driven solutions, Immunic is committed to enhancing treatment options for individuals suffering from chronic inflammatory and autoimmune conditions. Investors and partners are encouraged to stay informed about the company鈥檚 journey and future developments by visiting the official website and reviewing the privacy policy available at https://imux.com/privacy-policy/. This strategic funding round marks an exciting chapter in Immunic鈥檚 evolution, reaffirming its role as a leader in the biotech sector and enhancing its capacity to deliver groundbreaking therapies that could redefine standard care practices in autoimmune and inflammatory disorders.
Immunic Therapeutics Secures $5.1M to Accelerate Development of Novel Oral Autoimmune Therapies
Recently funded 路 $5.1MBiotechnology
Get the full Immunic Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
